Innovation Days
About
Research
Products
Investors
Careers
Agenda
fr
Press Releases
Our latest news and press releases
All
2022
2021
2020
2019
2018
2017
02
Dec
2019
16:30 E.S.T.
1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Read more
20
Nov
2019
16:30 E.S.T.
Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells
Read more
13
Nov
2019
16:30 E.S.T.
Cellectis Publishes Creation of “Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer in Nature Communications
Read more
06
Nov
2019
16:47 E.S.T.
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019
Read more
31
Oct
2019
16:30 E.S.T.
Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST
Read more
30
Oct
2019
16:30 E.S.T.
The Institut Pasteur and Cellectis extend exclusive license rights by granting genOway the authority to take action against infringement
Read more
29
Oct
2019
16:30 E.S.T.
First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma
Read more
01
Oct
2019
16:30 E.S.T.
Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates
Read more
06
Aug
2019
16:30 E.S.T.
Cellectis Reports Financial Results for Second Quarter and First Six Months 2019
Read more
08
Jul
2019
16:30 E.S.T.
Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way
Read more
1
2
Next